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Abstract
Purpose This study investigated the short- and long-term use
of medication for psychological distress after the diagnosis of
cancer.
Methods Longitudinal data from the Taiwan National Health
Insurance database were used to follow 35,137 cancer patients
for 2.5 years after being diagnosed in 2006 and 2007.
Results Among those patients who survived for at least
180 days, 20.9 % had used psychotropic medications; seda-
tives were the most frequently prescribed (14.3 %), followed
by antidepressants (5.5 %), anxiolytics (3.6 %), and antipsy-
chotics (2.7 %). Lung cancer, prostate cancer, and oral cancer
showed a significant association with the regular use of med-
ication in the first 180 days. Among patients who survived for
at least 2.5 years, 4.8 % still used psychotropic medication on
a regular basis. Lung cancer and prostate cancer were associ-
ated with such prolonged use.
Conclusions This longitudinal study found that the type of
cancer was significantly associated with the use of psychotro-
pic drugs after the diagnosis was made. It provided informa-
tion about the trajectory of that use and found that a small
number of patients were still using those medications after
2.5 years.
Keywords Psychologicaldistress .Psychotropicmedication .
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Abbreviations
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Introduction
Cancer is a leading cause of death in developed countries [1].
Its impact on mental health is also significant. Research has
shown that 25–30% of all newly diagnosed patients and those
with recurrent cancer experienced significantly elevated levels
of emotional distress, and around 50 % of those received psy-
chiatric diagnoses [2–5]. Studies of distress in long-term sur-
vivors have reported mixed results. Several [6–8] have dem-
onstrated persistent symptoms of depression, anxiety, pain,
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or fatigue, while others have indicated no difference in the
frequency of those symptoms from that in the general popu-
lation [9, 10].
Pharmacological therapy either alone or in combination with
psychosocial intervention has been demonstrated to be benefi-
cial for cancer patients with depression [11–13]. Previous stud-
ies have reported the prevalence rates for and the types of psy-
chotropic drugs prescribed for cancer patients; these studies
were based on cross-sectional data for prescriptions for seda-
tives, antidepressants, anxiolytics, and antipsychotics. The rea-
sons for the use of these drugs included depression, anxiety,
insomnia, pain, and treatment-related emesis [14, 15]. Little
research has investigated the association between type of cancer
and the use of psychotropic medication or long-term patterns of
use. Braun et al. [9] recently reported that cancer patients who
survived for 5 years or longer appeared to use psychotropic
medication at a rate similar to that of cancer-naïve controls. It
is unclear how the level of use might vary from time to time
among long-term cancer survivors and what factors might be
associated with persistently high use of psychotropic medica-
tions by these patients. We hypothesized that there might be
differences in the use of medication among patients with differ-
ent types of cancer and that the use of such medication would
be reduced and stable after a period of time.
The aims of this study, therefore, were to investigate the
short- and long-term use of medications for psychological
distress after the diagnosis of cancer and to determine what
factors were associated with such use.
Methods
This is a retrospective population study based on data from
Taiwan’sNational Health Insurance (NHI) databank.NHI covers
almost all Taiwanese for medical services in almost all outpatient
settings and hospitals [16]. Once a patient is diagnosed with a
malignancy, the National Health Insurance Administration
(NHIA) issues a catastrophic illness registry card to the patient
and then provides that patient with all NHI healthcare services
related to treatment of that cancer without copayments.
Data source
The NHI database includes comprehensive claims and regis-
tration data and has detailed information about health services,
procedures, and prescriptions provided through NHI. It also
includes data on diagnoses and background information on
patients, physicians, and healthcare institutions. The NHI sys-
tem codes diagnoses using the International Classification of
Diseases, Ninth Revision (ICD-9). The quality of NHI data is
considered to be reliable, because the NHIA routinely audits
data submitted by healthcare institutions in order to prevent
fraud.
The database we acquired contained person-level longitu-
dinal NHI claims and registration data for the entire national
population of patients who were newly diagnosed with cancer
between January 1, 2006 and June 30, 2007. We also acquired
longitudinal NHI registration data for healthcare institutions.
Study participants
We used SAS software version 9.1.3 (SAS Institute Inc., Cary,
NC) to extract, organize, and link each patient’s data. We
selected the date of the first cancer registry as the index date
for the beginning of observation (n = 79,868) but included
only patients with the ten most common types of cancer
(n = 57,224). Because we focused on the regular use of psy-
chotropic medication after the diagnosis of cancer, we exclud-
ed patients with a previous diagnosis of cancer and those who
had at least one prescription for medication for psychological
distress within the 2 years immediately prior to their index
date (n = 40,080). Finally, we excluded patients with missing
data for the essential variables in our study. For each patient in
the study (n = 35,137), we had a complete 2.5-year follow-up.
(Fig. 1).
Research variables
We classified the medications for psychological distress
as antidepressants, anxiolytics, sedatives, and antipsy-
chotics in accordance with the study of cancer patients
by Derogatis et al. [14]. Although several of these med-
ications are used to control chemotherapy-induced nau-
sea and vomiting, The National Comprehensive Cancer
Network recommends that they be used only temporar-
ily for this [17]. Control of emesis would not be a long-
term indication. Our outcome variables were binary var-
iables reflecting regular use of psychotropic medication
in the five 180-day periods after the diagnosis of cancer.
NHI regulations require that prescriptions be renewed
every 180 days. A value of 1 indicated regular use
and a value of 0 denoted non-regular use. We defined
regular medication use in a period as a medication pos-
session ratio (MPR) ≧50 % for the period. MPR is the
ratio of Bthe number of days for which medication is
prescribed in a period^ to Bthe number of days alive in
that period.^ MPR is a common index for measuring
medication adherence, and it is also a suitable outcome
measure for investigating the long-term or regular use of
medication [18]. Many studies of medication adherence
in chronic disease adopted a MPR≧80 % as the indica-
tor of regular use [19]; however, we believed that a
MPR≧50 % for psychotropic medication was already a
sign of severe psychiatric distress and consistent with
other studies [20, 21].
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We used NHI data to establish a set of factors which might
potentially influence the use of mediation for psychological dis-
tress. Patient characteristics at the time of the diagnosis of cancer
included gender, age, and type of cancer; rather than using the
more general Charleston Comorbidity Index, we selected comor-
bid conditions generally associated with use of medications for
psychological distress. These included diabetes mellitus (DM),
hypertension, chronic obstructive pulmonary disease (COPD),
chronic liver disease, coronary arterial disease (CAD), and cere-
bral vascular accident (CVA) [22]. We created a binary variable
to denote the existence of comorbidity for each of these condi-
tions and also a binary variable to indicate the existence of at least
one of these conditions.
We generated a set of binary variables to indicate the
level of urbanization of a patient’s NHI registration lo-
cation according to the local population density and the
local pattern of industry [23]. With regard to socioeco-
nomic status, we included a set of categorical variables
showing the position of NHI registration and the salary
tertile. The project was approved by the Institutional
Review Board (IRB) of National Taiwan University
Hospital (NTUH-REC No. 201307046W). All individual
identification numbers were scrambled to protect
privacy.
Statistical analysis
Stata Software version 9 was used (StataCorp, College
Station, TX) for descriptive statistics and multivariable regres-
sion analysis. Binary variables indicating use of medication
were reported as counts and percentages. The chi-square test
was used to assess differences between subgroups of cancer
patients.
On the basis of the MPR levels in the five 180-day
periods after the diagnosis of cancer, we defined pat-
terns of long-term medication use. We regarded the per-
sistent regular use of psychotropic medication as regular
use for all the five 180-day periods after the diagnosis.
Fig. 1 The process of selection
of study subjects
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We used logit regression analysis to identify factors as-
sociated with regular medication use in the first 180 days
after diagnosis, as well as factors associated with per-
sistent regular medication use over the five 180-day
periods after the diagnosis. Statistical significance was
set as p ≤ 0.05.
Results
Study participants and their survival rates
Among patients with the ten most common types of cancer,
17.5 % died within 180 days after the diagnosis. Table 1
shows the study subjects’ demographic, socioeconomic, and
clinical characteristics separately for patients who survived at
least 180 days and for those who died within 180 days after
the diagnosis. The data show that the two groups of patients
had significant differences for each characteristic we
investigated.
Table 2 shows the survival rates over the 2.5 years follow-
ing the diagnosis of cancer for different types of cancer, sep-
arately by gender. Among male patients, those with lung can-
cer and those with liver cancer had the poorest prognosis.
Only 18.3 % of male lung cancer patients and 35.1 % of male
liver cancer patients survived for 2.5 years after that diagnosis,
while 80.6 % of prostate cancer patients survived at least
2.5 years. Among female patients, those with lung cancer
and those with liver cancer also had a poor prognosis. Only
30.6 % of female lung cancer patients and 40.3 % of female
liver cancer patients survived for 2.5 years after that diagnosis,
while 92.3 % of breast cancer patients survived at least
2.5 years.
Proportions of cancer patients who regularly used
psychotropic medications
Supplemental Table S1 shows the proportions of patients
who regularly used medication for psychological distress
among those who survived at least 180 days after the
diagnosis of cancer. The table reports the proportions
for different types of cancer and for all ten common
types of cancer combined, as well as the proportions
for all types of psychotropic medications combined and
separately for antidepressants, anxiolytics, sedatives, and
antipsychotics.
The overall rate of use during the first 180-day peri-
od was 20.88 % in the population that survived at least
180 days. Among the four drug classes, sedatives were
most commonly prescribed for each type of cancer ex-
cept prostate cancer; antidepressants were the second
most common for each type of cancer except prostate
cancer. Because many patients with prostate cancer used
imipramine for enuresis, and imipramine is classified as
an antidepressant, antidepressants were the drug class
most commonly prescribed for prostate cancer.
Lung cancer patients had the highest overall use of psycho-
tropic mediation in the first 180 days, as 30.1 % of them took
medication regularly. Head and neck cancer patients ranked
second at 28.1 %. The lowest proportion of regular use,
13.3 %, was for patients with skin cancer.
The overall use of medication for psychological dis-
tress decreased slightly over time during the first 2.5-
year period after diagnosis (Fig. 2). Patients with liver
cancer showed an increasing trend for the use of med-
ication, while patients with oral cancer showed a de-
creasing trend. Both lung cancer and prostate cancer
patients had a high use of medication, and both of these
groups showed a fluctuating trend in use. Both genders
showed similar trends (data not shown).
Factors associated with regular use of psychotropic
medication in the first 180-day period after diagnosis
Table 3 shows the factors associated with regular use of psy-
chotropic medication in the first 180 days after diagnosis in
male cancer patients. Compared to skin cancer, oral cancer
(odds ratio (OR) = 2.8, p < 0.001) and lung cancer
(OR = 2.7, p < 0.001) were associated with a significantly
greater use of psychotropic medication. Prostate cancer
(OR = 2.5, p < 0.001) and stomach cancer (OR = 1.4,
p < 0.001) were also associated with greater use of medica-
tion. Comorbidity at the time of cancer diagnosis was also
associated with a higher level of medication use (OR = 1.1,
p < 0.01). Male cancer patients in big cities appeared to use
medication less (OR = 0.8, p < 0.01). The region of location of
NHI registration was also an influential factor.
Regarding factors associated with the regular use of
psychotropic medication in the first 180 days after di-
agnosis by female cancer patients, compared to skin
cancer, lung cancer (OR = 2.6, p < 0.001), oral cancer
(OR = 2.0, p < 0.01), cervical cancer (OR = 1.6,
p < 0.01), and liver cancer (OR = 1.5, p < 0.05) were
all associated with a greater use of psychotropic medi-
cation (details not shown). Women under 35 used less
medication (p < 0.05). Women with better occupations
(e.g., government employees, teachers, or employees
with regular employers) or women with NHI registration
through local governments also tended to use less med-
ication (p < 0.05).
Long-term patterns of use of medication by cancer
patients who survived at least 2.5 years after diagnosis
With regard to the pattern of long-term use of psycho-
tropic medication shown in Table 4, on average, 4.8 %
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Table 1 Comparison of the characteristics of patients who survived at least 180 days and those who passed awaywithin 180 days after the diagnosis of
cancer
Characteristics Patients surviving
at least 180 days
Patients passing away
within 180 days
p value for χ2 test
n % n %
Gender p < 0.001
Male 15,641 46.03 4534 73.68
Female 13,342 53.97 1620 26.32
Age at cancer diagnosis (in years) p < 0.001
<35 1048 3.62 106 1.72
35–44 4047 13.96 408 6.63
45–54 7141 24.64 914 14.85
55–64 6243 21.54 1089 17.70
65–74 6149 21.22 1558 25.32
75–84 3816 13.17 1636 26.58
≥85 539 1.86 443 7.20
Region of the NHI registration location at cancer diagnosis p < 0.001
Taipei region 9902 34.16 1843 29.95
Northern region 3616 12.48 744 12.09
Central 4917 16.97 1057 17.18
Southern 4921 16.98 1201 19.52
The farthest South (two counties) 4851 16.74 1102 17.91
Eastern 776 2.68 207 3.36
Urbanization level of the NHI registration location at cancer diagnosis p < 0.001
Big city 14,391 49.65 2718 44.17
Small city or town 9997 34.49 2212 35.94
Remote or rural area 4595 15.85 1224 19.89
Occupation type in the NHI registry at cancer diagnosis p < 0.001
Government employee or teacher 1581 5.45 271 4.4
NHI registration through employers of other types 9153 31.58 1525 24.78
NHI registration through labor unions 5445 18.79 892 14.49
Veterans or their dependents 252 0.87 62 1.01
Family dependents with no jobs 294 1.01 92 1.49
NHI registration through local governments 5349 18.46 1342 21.81
Members of families in poverty/residents in religious or charitable institutions 175 0.60 64 1.04
NHI registration through farmers/fishermen/crewmen unions 6734 23.23 1906 30.97
Salary class in the NHI registry at cancer diagnosis p < 0.001
The bottom tertile of the population 12,460 42.99 3096 50.31
The middle tertile 10,694 36.90 2414 39.23
The top tertile 5829 20.11 644 10.46
Comorbidity at cancer diagnosis
Diabetes p < 0.001
No 25,839 89.15 5282 85.83
Yes 3144 10.85 872 14.17
Hypertension p < 0.001
No 22,362 77.15 4522 73.48
Yes 6623 22.85 1632 26.52
Ischemic heart disease p < 0.001
No 27,442 94.68 5649 91.79
Yes 1541 5.32 505 8.21
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Table 1 (continued)
Characteristics Patients surviving
at least 180 days
Patients passing away
within 180 days
p value for χ2 test
n % n %
Comorbidity at cancer diagnosis
Cerebrovascular accident p < 0.001
No 27,904 96.28 5686 92.40
Yes 1079 3.72 468 7.60
Chronic obstructive pulmonary disease p < 0.001
No 27,892 96.24 5602 91.03
Yes 1091 3.76 552 8.97
Chronic liver disease/cirrhosis p < 0.001
No 25,440 87.78 4423 71.87
Yes 3543 12.22 1731 28.13
Cancer type p < 0.001
Malignant neoplasm of rectum and rectosigmoid colon 6459 22.29 646 10.50
Malignant neoplasm of breast 5503 18.99 93 1.51
Malignant neoplasm of liver and intrahepatic bile ducts 3107 10.72 2296 37.31
Malignant neoplasm of trachea, bronchus, and lung 3072 10.60 1896 30.81
Malignant neoplasm of lip, oral cavity, and pharynx 4103 14.16 373 6.06
Malignant neoplasm of stomach 1698 5.86 641 10.42
Malignant neoplasm of prostate 1945 6.71 83 1.35
Malignant neoplasm of cervix uteri 1611 5.56 59 0.96
Malignant melanoma of skin 838 2.89 35 0.57
Malignant neoplasm of body of uterus 647 2.23 32 0.52
Table 2 Post-diagnosis survival rates among cancer patients, for the ten most common types of cancer
180-day survival rate 1-year survival rate 1.5-year survival rate 2-year survival rate 2.5-year survival rate
Cancer type (n) at diagnosis % (n) % (n) % (n) % (n) % (n)
Male
Colon (n = 4296) 91.2 (3919) 85.7 (3682) 81.0 (3481) 76.8 (3299) 72.7 (3125)
Liver (n = 4229) 56.1 (2372) 47.5 (2007) 42.0 (1778) 38.6 (1633) 35.1 (1485)
Oral (n = 4188) 91.7 (3839) 80.2 (3357) 70.9 (2968) 66.2 (2771) 63.4 (2657)
Lung (n = 3366) 57.8 (1946) 40.3 (1358) 29.5 (992) 22.9 (771) 18.3 (617)
Prostate (n = 2028) 95.9 (1945) 92.7 (1880) 88.5 (1794) 84.8 (1720) 80.6 (1635)
Stomach (n = 1548) 73.1 (1131) 62.0 (960) 54.3 (841) 49.0 (759) 45.9 (710)
Skin (n = 513) 94.0 (482) 89.3 (458) 85.0 (436) 81.9 (420) 80.1 (411)
Female
Breast (n = 5589) 98.3 (5496) 97.1 (5427) 95.6 (5344) 93.9 (5246) 92.3 (5156)
Colon (n = 2809) 90.4 (2540) 85.7 (2407) 81.1 (2279) 76.6 (2151) 72.9 (2049)
Cervical (n = 1670) 96.5 (1611) 92.0 (1537) 88.1 (1471) 84.9 (1417) 82.6 (1379)
Lung (n = 1602) 70.3 (1126) 56.2 (901) 44.9 (720) 37.2 (596) 30.6 (491)
Liver (n = 1174) 62.6 (735) 53.8 (632) 48.9 (574) 44.5 (522) 40.3 (473)
Stomach (n = 791) 71.7 (567) 59.4 (470) 51.1 (404) 46.4 (367) 43.9 (347)
Uterus (n = 679) 95.3 (647) 92.6 (629) 90.0 (611) 88.1 (598) 86.5 (587)
Skin (n = 360) 98.9 (356) 96.4 (347) 93.1 (335) 91.4 (329) 89.4 (322)
Oral (n = 288) 91.7 (264) 80.9 (233) 73.3 (211) 69.8 (201) 68.1 (196)
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of all patients used psychotropic drugs regularly in all
five 180-day periods, while 62.8 % had no period with
regular use in all five 180-day periods.
Comparison among types of cancer indicates that
lung and prostate cancer patients were the two groups
at higher risk for persistent regular use of psychotropic
medication. Males with oral cancer patients also showed
high use in the early periods after the diagnosis.
Supplemental Table S2.1 presents factors associated
with persistent regular use of psychotropic medications
in the five 180-day periods after the diagnosis in male
cancer patients. Compared to skin cancer, lung cancer
(OR = 3.8, p < 0.001), oral cancer (OR = 3.1,
p < 0.01), and prostate cancer (OR = 2.7, p < 0.01)
were associated with significantly greater use of psycho-
tropic medication. Comorbidity at the time of the diag-
nosis of cancer was also related to a higher level of
medication use (OR = 1.3, p < 0.01). No demographic
or socioeconomic factors were statistically significant
for male cancer patients with regard to level of drug
use.
Data about the use of psychotropic medications in the
five 180-day periods after the diagnosis by female cancer
patients are shown in Supplemental Table S2.2. Lung
cancer (OR = 3.7, p < 0.001) was associated with a
higher demand for psychiatric medication. Comorbidity
at the time of the diagnosis was also associated with a
higher level of medication use (OR = 1.4, p < 0.05).
Compared to women in the bottom salary tertile in the
NHI registry, women in a higher salary grade tended to
use less medication (p < 0.05).
Discussion
Among cancer patients who survived at least 180 days
after the diagnosis, 20.9 % used psychotropic medica-
tion regularly during that period, and sedatives were
used most frequently. The proportion of patients who
used psychotropic mediation regularly remained stable
over the 2.5 years after the diagnosis. Among patients
who survived at least 2.5 years, 4.8 % still used psy-
chotropic medications on a regular basis. Lung cancer
and prostate cancer were associated with such persistent
use.
Instead of examining the use of psychotropic medication
during a specific period of cancer treatment, this study inves-
tigated the regular use of these drugs after the diagnosis and
focused on patients with newly diagnosed cancer and newly
diagnosed psychological distress. In Taiwan, the Distress
Thermometer has become a routine screening tool used with
cancer patients nationwide, and hospitals provide psychoso-
cial support accordingly [24]. In a survey administered to
1579 patients admitted for cancer treatment, 51 % reported
that they had been prescribed at least one psychotropic med-
ication [14]. A longitudinal 8-month follow-up study of
Chinese women after surgery for breast cancer [25] showed
a declining trend in psychological distress after surgery, but
49 % of their study participants had psychological distress
over those 8 months. Some Western studies reported similar
findings [26]. A large survey of newly diagnosed cancer pa-
tients (n = 4496) showed that the overall prevalence rate of
psychological distress was 35.1 %, and the rates for different
types of cancer varied; the rates were 43.4 % for lung cancer,
Fig. 2 Proportions of patients regularly using medication for psychological distress in the five 180-day periods after cancer onset
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Table 3 Factors associated with
regular use of psychotropic
medications in the first 180-day
period after the diagnosis of
cancer, for male patients who
survived 180 days
Explanatory variables OR 95 % CI
The type of cancer at diagnosisa (reference: skin cancer)
Colon cancer 1.322 0.999–1.748
Liver cancer 1.243 0.931–1.659
Oral cancer 2.789 *** 2.100–3.705
Lung cancer 2.666 *** 2.001–3.551
Prostate cancer 2.521 *** 1.908–3.329
Stomach cancer 1.429 * 1.050–1.944







Region of the NHI registration location at the onset of cancer (reference: East)
Taipei region 0.811 0.647–1.017
North except Taipei 0.686 ** 0.542–0.867
Central 0.822 0.657–1.028
South 0.667 *** 0.532–0.836
The farthest south (Kaohsiung and Ping-Tung) 0.590 *** 0.468–0.742
Urbanization level of the NHI registration location at the onset of cancer
(reference: remote or rural area)
Big city 0.825 ** 0.724–0.940
Small city or town 0.919 0.818–1.033
Occupation type in the NHI registry at the onset of cancer
(reference: NHI registration through farmers/fishermen/crewmen unions)
Government employee or teacher 0.938 0.747–1.178
NHI registration through employers of other types 0.984 0.839–1.154
NHI registration through labor unions 1.112 0.959–1.290
Veterans or their dependents 0.953 0.641–1.416
Family dependents with no jobs 1.256 0.833–1.894
NHI registration through local governments 1.007 0.840–1.207
Members of families in poverty/residents in religious or charitable
institutions
1.152 0.714–1.858
Salary class in the NHI registry at the onset of cancer
(reference: the bottom tertile of the population)
The middle tertile 0.959 0.835–1.102
The top tertile 0.910 0.799–1.037
Comorbidity (reference: none)
Some comorbidity 1.116 ** 1.027–1.212
No. of observations 15,634
Breast cancer 1.260 0.917–1.733
Colon cancer 1.283 0.929–1.773
Cervical cancer 1.644 ** 1.181–2.288
Lung cancer 2.592 *** 1.859–3.614
Liver cancer 1.530 * 1.070–2.188
Stomach cancer 1.448 0.999–2.099
Uterus cancer 1.263 0.870–1.834
Oral cancer 2.049 ** 1.353–3.103
Age in years (reference <35)
35–44 1.486 ** 1.130–1.954
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35.4 % for liver cancer, 35.1 % for head and neck cancer,
31.6 % for colon cancer, 30.5 % for prostate cancer, and
29.6 % for gynecological cancer [3].
Our study found that 20.9 % of patients who sur-
vived at least 180 days used psychiatric medication in
those first 180 days. Because our study focused on the
regular use of psychotropic medication, and controlled
for the influences of pre-existent malignancy and mental
problems, it is not surprising that we found lower prev-
alence rates for the use of psychotropic medications
than the surveys mentioned above.
Clusters of psychological symptoms and classes
of psychiatric drugs in cancer patients
Major symptoms of psychological distress among cancer pa-
tients include sleep disturbance, anxiety, depression, and so-
matization [14]. As shown in one prospective study, 36.6 % of
cancer patients reported symptoms of insomnia, and 43%met
the diagnostic criteria for insomnia syndrome during their first
cycle of chemotherapy [27]. Our results with regard to the
distribution of classes of psychotropic medications clearly
demonstrated this. In the first 180-day period after the
Table 3 (continued)
Explanatory variables OR 95 % CI
45–54 1.826 *** 1.401–2.381
55–64 1.768 *** 1.347–2.322
65–74 1.623 ** 1.223–2.152
75–84 1.402 * 1.034–1.899
≧85 1.722 * 1.115–2.660
Region of the NHI registration location at the onset of cancer (reference: East)
Taipei region 1.078 0.804–1.445
North except Taipei 0.781 0.575–1.061
Central 0.927 0.690–1.246
South 0.938 0.698–1.262
The farthest south (Kaohsiung and Ping-Tung) 0.912 0.676–1.230
Urbanization level of the NHI registration location at the onset of cancer
(reference: remote or rural area)
Big city 0.897 0.761–1.057
Small city or town 0.965 0.830–1.121
Occupation type in the NHI registry at the onset of cancer
(reference: NHI registration through farmers/fishermen/crewmen unions)
Government employee or teacher 0.746 * 0.580–0.960
NHI registration through employers of other types 0.835 * 0.701–0.994
NHI registration through labor unions 0.864 0.729–1.024
Veterans or their dependents 0.798 0.418–1.525
Family dependents with no jobs 1.231 0.826–1.835
NHI registration through local governments 0.814 * 0.663–0.998
Members of families in poverty/residents in religious or charitable
institutions
0.948 0.534–1.682
Salary class in the NHI registry at the onset of cancer
(reference: bottom tertile of the population)
The middle tertile 0.880 0.765–1.012
The top tertile 0.874 0.758–1.008
Comorbidity (reference: none)
Some comorbidity 1.002 0.903–1.111
No. of observations 13,342
Log-likelihood ratio test statistic for model significance Wald χ2
(31) = 191.35-
***
CI confidence interval, OR odds ratio
*p < 0.05, **p < 0.01, ***p < 0.001
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diagnosis, sedatives for insomnia were the most commonly
prescribed drugs.
Trends in the regular use of medication for psychological
distress over time after the diagnosis of cancer
Patients with different types of cancer showed different
trends in the regular use of medication for psychological
distress over time after the diagnosis. Two types of can-
cer were particularly noteworthy: liver cancer and oral
cancer. Among patients with liver cancer, the proportion
of regular use was 17.0 % in the first 180-day period,
and it increased to 23.0 % in the fifth 180-day period.
For patients with oral cancer, the proportion was 28.1 %
in the first 180-day period, and it decreased to 20.2 %
in the fifth 180-day period. Determination of the reasons
for this difference requires further study.
Information about an individual patient’s long-term
pattern of the regular use of medication sheds light on
the types of cancer associated with persistent psycholog-
ical distress. Our data indicated that 4.75 % of cancer
patients who survived for at least 2.5 years had persis-
tent psychological distress, and patients with lung or
prostate cancer were more likely to continue to use psy-
chotropic medications. Without specific data for individ-
ual patients, the reasons for persistent distress are un-
known. A previous study showed that the prevalence of
psychological distress did not change during the year
after curative resection in patients with lung cancer
[28]; however, a recent study by Braun et al. [9] found
that the level of psychological distress among 5-year
cancer survivors was no different from that of cancer-
naïve controls. Epstein et al. [29] did note that heavy
drinking and heavy smoking were associated with both
depression and specific types of cancer; however, infor-
mation about a history of drinking or smoking was not
available to us. Our study provides some indication of
the prevalence of distress in the intervening years; how-
ever, the determination of which patients may be at risk
for psychological distress requires further study.
Clinically, Hammerlid et al. reported a high incidence of
anxiety soon after the diagnosis of head and neck cancer, and
depression reached a peak about 3 months after the initial
treatment of these patients; the rates of both returned to near
pre-treatment levels within 12 months. [30]. Similarly, our
results showed a high demand for medication for psycholog-
ical distress (28 %) in the first 6 months after diagnosis and a
lower level of demand (23 %) thereafter. Cancer therapy in-
cluding surgery, radiation, and chemotherapy or combinations
of these can be an important factor since treatment is often
finished within 6 months. These first 6 months for newly
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period for psychological support and a systematic assessment
of patients’ distress and need for supportive care is important.
On the other hand, we found that patients with lung cancer
and prostate cancer used psychotropic medication regularly
(approximately 30 %) during both the short time interval
and the long time interval. Dinh et al. reported the association
between androgen deprivation therapy and depression in pa-
tients with localized prostate cancer, and the risk of depression
increased with the duration of that therapy from 12 % with
fewer than 6months of treatment, to 26%with 7 to 11months,
and 37 % with longer than 12 months of treatment [31]. A
survey done in England by Ream et al. found high levels of
psychological distress in men living with prostate cancer for 2
to 24months prior to the survey and receiving various kinds of
treatment; however, they did not mention the trend of this
unmet need [32]. Our findings showed a consistent high level
of medication use as a result of psychological distress for a
long period of time. Although we were unable to identify the
treatment modality for each patient with prostate cancer, the
Cancer Registry did show that a majority of our patients had
undergone androgen deprivation therapy by surgery, radia-
tion, hormonal therapy, or a combination of these. A strategy
to improve long-term health-related quality of life including
the need for medication for psychological distress is clearly
warranted for men with prostate cancer.
In our study, patients with lung cancer showed a trend in
medication use similar to that of patients with prostate cancer.
Rauma et al. reported a permanent reduction in health-related
quality of life including depression and psychological distress
among survivors of non-small cell lung cancer. [33] A high
percentage of lung cancer in Taiwan is adenocarcinoma, how-
ever [34]. This suggests that an assessment for psychological
distress is important but also depends on the type of cancer
and the therapeutic modality [35].
This study did have several limitations. Neither clinical
diagnoses of the psychological disorders nor the stage of
cancer at the time of diagnosis was cited. Treatment modali-
ties and treatment outcomes were not noted in the record.
There was no comparison data for the use of psychotropic
medications by the general population. Because patients with
a catastrophic illness registry card receive all medications
without copayment from their surgeon, oncologist, and/or
psychiatrist, there is no information as to whether the pre-
scription was initiated by a physician or requested by the
patient. The specialties of the prescribing physicians were
not indicated; however, a previous study showed that missed
rates of psychiatric morbidity did not differ significantly by
physician specialty or primary cancer site [36]. Finally, the
assumption that medication prescription equals medication
consumption is not always the case. The trend of the demand
in this report, however, indicated that physicians prescribed
medications when patients required them and stopped pre-
scribing them when they did not.
Conclusions
This longitudinal study found that the type of cancer was
significantly associated with the use of psychotropic drugs
after the diagnosis. It provided information on the trajectory
of that use and found that a small number of patients were still
using these medications after 2.5 years. The findings
highlighted the need for ongoing assessments of the level of
psychological distress among cancer patients.
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